32.24
price down icon1.71%   -0.56
pre-market  Pre-market:  33.99   1.75   +5.43%
loading
Cg Oncology Inc stock is traded at $32.24, with a volume of 549.44K. It is down -1.71% in the last 24 hours and down -11.53% over the past month. CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
See More
Previous Close:
$32.80
Open:
$32.65
24h Volume:
549.44K
Relative Volume:
0.88
Market Cap:
$2.18B
Revenue:
-
Net Income/Loss:
$-64.16M
P/E Ratio:
-
EPS:
-
Net Cash Flow:
$-69.06M
1W Performance:
-8.28%
1M Performance:
-11.53%
6M Performance:
+8.44%
1Y Performance:
+0.00%
1-Day Range:
Value
$31.53
$33.05
1-Week Range:
Value
$31.53
$36.05
52-Week Range:
Value
$25.77
$50.23

Cg Oncology Inc Stock (CGON) Company Profile

Name
Name
Cg Oncology Inc
Name
Phone
(949) 419-6203
Name
Address
400 SPECTRUM CENTER DRIVE, IRVINE
Name
Employee
61
Name
Twitter
Name
Next Earnings Date
Name
Latest SEC Filings
Name
CGON's Discussions on Twitter

Compare CGON with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
CGON 32.24 2.18B 0 -64.16M -69.06M 0.00
VRTX 451.23 115.74B 10.63B -479.80M -1.35B 13.33
REGN 743.35 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 591.82 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 248.79 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 102.14 24.49B 3.30B -501.07M 1.03B 11.54

Cg Oncology Inc Stock (CGON) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-14-24 Initiated H.C. Wainwright Buy

Cg Oncology Inc Stock (CGON) Latest News

pulisher
Nov 20, 2024

CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 25th Annual Meeting - The Manila Times

Nov 20, 2024
pulisher
Nov 20, 2024

CG Oncology to Present Phase 3 Trial Results for Bladder Cancer Treatment at SUO Meeting | CGON Stock News - StockTitan

Nov 20, 2024
pulisher
Nov 20, 2024

CG Oncology, Inc. to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology 25th Annual Meeting - Marketscreener.com

Nov 20, 2024
pulisher
Nov 18, 2024

CG Oncology, Inc. (NASDAQ:CGON) Sees Large Decline in Short Interest - MarketBeat

Nov 18, 2024
pulisher
Nov 18, 2024

CG Oncology FY2024 EPS Estimate Lifted by Cantor Fitzgerald - MarketBeat

Nov 18, 2024
pulisher
Nov 16, 2024

Los Angeles Capital Management LLC Takes $832,000 Position in CG Oncology, Inc. (NASDAQ:CGON) - MarketBeat

Nov 16, 2024
pulisher
Nov 16, 2024

Lifesci Capital Boosts Earnings Estimates for CG Oncology - Defense World

Nov 16, 2024
pulisher
Nov 15, 2024

FY2024 EPS Estimates for CG Oncology Raised by HC Wainwright - MarketBeat

Nov 15, 2024
pulisher
Nov 15, 2024

CG Oncology FY2024 EPS Forecast Increased by Lifesci Capital - MarketBeat

Nov 15, 2024
pulisher
Nov 14, 2024

CG Oncology, Inc. (CGON) Quarterly 10-Q Report - Quartz

Nov 14, 2024
pulisher
Nov 14, 2024

CG Oncology Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance

Nov 14, 2024
pulisher
Nov 13, 2024

CG Oncology (NASDAQ:CGON) Releases Earnings Results, Beats Estimates By $0.06 EPS - MarketBeat

Nov 13, 2024
pulisher
Nov 12, 2024

HC Wainwright Reiterates "Buy" Rating for CG Oncology (NASDAQ:CGON) - MarketBeat

Nov 12, 2024
pulisher
Nov 12, 2024

CG Oncology Posts $20.4M Loss, Maintains $540M Cash Reserve Through 2027 | CGON Stock News - StockTitan

Nov 12, 2024
pulisher
Nov 11, 2024

CG Oncology Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Muscle-Invasive Bladder Cancer - The Manila Times

Nov 11, 2024
pulisher
Nov 11, 2024

CG Oncology Announces Nature Medicine Publication of Phase 1b Study Results Evaluating - The Bakersfield Californian

Nov 11, 2024
pulisher
Nov 11, 2024

CG Oncology, Inc. Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Muscle-Invasive Bladder Cancer - Marketscreener.com

Nov 11, 2024
pulisher
Nov 11, 2024

TimesSquare Capital Management LLC Purchases 94,010 Shares of CG Oncology, Inc. (NASDAQ:CGON) - MarketBeat

Nov 11, 2024
pulisher
Nov 10, 2024

CG Oncology, Inc. (NASDAQ:CGON) Receives Consensus Recommendation of “Buy” from Analysts - Defense World

Nov 10, 2024
pulisher
Nov 10, 2024

CG Oncology, Inc. (NASDAQ:CGON) Receives $63.88 Consensus Target Price from Analysts - MarketBeat

Nov 10, 2024
pulisher
Nov 06, 2024

CG Oncology, first biotech IPO for 2024, surges on trading debut - MSN

Nov 06, 2024
pulisher
Nov 04, 2024

Vanguard Group Inc's Strategic Acquisition of CG Oncology Inc Sh - GuruFocus.com

Nov 04, 2024
pulisher
Oct 31, 2024

10 Best IPO Stocks To Buy Heading into 2025 - Insider Monkey

Oct 31, 2024
pulisher
Oct 30, 2024

CG Oncology To Report Final Results From CORE-001 Bladder Cancer Study Next Month - RTTNews

Oct 30, 2024
pulisher
Oct 29, 2024

CG Oncology, Inc. (NASDAQ:CGON) Short Interest Down 14.5% in October - Defense World

Oct 29, 2024
pulisher
Oct 25, 2024

UBS Initiates Coverage of CG Oncology (CGON) with Buy Recommendation - MSN

Oct 25, 2024
pulisher
Oct 24, 2024

CG Oncology (NASDAQ:CGON) Coverage Initiated by Analysts at UBS Group - MarketBeat

Oct 24, 2024
pulisher
Oct 21, 2024

Oncolytic Adenovirus Market Targets USD 250 Billion Valuation by 2033 at a 7.5% of CAGR - PharmiWeb.com

Oct 21, 2024
pulisher
Oct 16, 2024

CG Oncology, Inc. (NASDAQ:CGON) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat

Oct 16, 2024
pulisher
Oct 15, 2024

Oncolytic Virus Market Size is Set for Rapid Growth as Innovative - openPR

Oct 15, 2024
pulisher
Oct 14, 2024

17,595 Shares in CG Oncology, Inc. (NASDAQ:CGON) Acquired by SG Americas Securities LLC - MarketBeat

Oct 14, 2024
pulisher
Oct 10, 2024

Down rounds don’t aid post-IPO performance - BioCentury

Oct 10, 2024
pulisher
Oct 08, 2024

CG Oncology (NASDAQ:CGON) Earns "Buy" Rating from Bank of America - MarketBeat

Oct 08, 2024
pulisher
Oct 07, 2024

The Potential Rise in the Price of Cg Oncology Inc. (CGON) following insiders activity - Knox Daily

Oct 07, 2024
pulisher
Oct 07, 2024

Get in on Cg Oncology Inc.’s (CGON) buy-in window today! - SETE News

Oct 07, 2024
pulisher
Oct 05, 2024

Renaissance Technologies LLC Grows Position in CG Oncology, Inc. (NASDAQ:CGON) - MarketBeat

Oct 05, 2024
pulisher
Oct 04, 2024

Marshall Wace LLP Acquires New Shares in CG Oncology, Inc. (NASDAQ:CGON) - MarketBeat

Oct 04, 2024
pulisher
Oct 04, 2024

Companies Like CG Oncology (NASDAQ:CGON) Are In A Position To Invest In Growth - Simply Wall St

Oct 04, 2024
pulisher
Oct 03, 2024

Multiple players rev their Engenes in bladder cancer - BioWorld Online

Oct 03, 2024
pulisher
Oct 03, 2024

Point72 Asset Management L.P. Sells 75,827 Shares of CG Oncology, Inc. (NASDAQ:CGON) - MarketBeat

Oct 03, 2024
pulisher
Oct 03, 2024

Want To Improve Study Startup? Get More Efficient - Clinical Leader

Oct 03, 2024
pulisher
Oct 01, 2024

We Think CG Oncology (NASDAQ:CGON) Can Afford To Drive Business Growth - Yahoo Finance

Oct 01, 2024
pulisher
Sep 30, 2024

How does Cg Oncology Inc. (CGON) change from a tortoise to a hare? - SETE News

Sep 30, 2024
pulisher
Sep 30, 2024

RBC Capital Mkts initates Cg Oncology Inc. (CGON) stock to an Outperform - Knox Daily

Sep 30, 2024
pulisher
Sep 30, 2024

CG Oncology, Inc. (NASDAQ:CGON) Shares Sold by Perceptive Advisors LLC - MarketBeat

Sep 30, 2024
pulisher
Sep 28, 2024

Ensign Peak Advisors Inc Buys New Holdings in CG Oncology, Inc. (NASDAQ:CGON) - MarketBeat

Sep 28, 2024
pulisher
Sep 27, 2024

Wall Street SWOT: CG Oncology stock poised for growth in bladder cancer market - Investing.com

Sep 27, 2024
pulisher
Sep 27, 2024

Midday Stock Roundup: Indie Shares Down 5% - Orange County Business Journal

Sep 27, 2024
pulisher
Sep 27, 2024

Wall Street SWOT: CG Oncology stock poised for growth in bladder cancer market By Investing.com - Investing.com South Africa

Sep 27, 2024
pulisher
Sep 26, 2024

Goldman Sachs maintains $52 target on CG Oncology shares By Investing.com - Investing.com Canada

Sep 26, 2024
pulisher
Sep 26, 2024

Deerfield Management Company L.P. Series C Increases Stake in CG Oncology, Inc. (NASDAQ:CGON) - MarketBeat

Sep 26, 2024

Cg Oncology Inc Stock (CGON) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$71.05
price up icon 0.69%
$18.62
price down icon 6.90%
$36.94
price down icon 0.94%
$364.33
price up icon 1.00%
$194.26
price up icon 3.46%
$102.14
price down icon 4.00%
Cap:     |  Volume (24h):